The aim is to evaluate the effectiveness of high-dose chemotherapy with autologous stem-cell rescue for treating multiple myeloma.
Intervention: high-dose chemotherapy with autologous stem-cell rescue
Population: patients with multiple myeloma under 65 years of age
High-dose therapy demonstrated effectiveness as first-line treatment for multiple myeloma in the studied population.
Abstract
High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.